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Abstract
Introduction Patients with congenital agammaglobulinemia,
characterized by a defect in B lymphocyte differentiation
causing B alymphocytosis, require life-long IgG replacement.
There is scant literature regarding the effectiveness of IgG
treatment at preventing mucosal (particularly sinopulmonary
tract) infection and whether current management adequately
restores “normal” health and quality of life (QoL). We aimed
to document infective episodes pre- and post-commencing
IgG replacement, determine any change in lung function and
structure and assess respiratory status and QoL in a cohort of
patients treated in Newcastle.
Methods Clinical data were extracted frommedical records of
15 patients identified from the immunology database, focus-
ing on infective episodes, serial chest CT and spirometry re-
sults. Thirteen patients completed a selection of standardized
and validated questionnaires assessing physical health, respi-
ratory health and QoL.
Results Pediatric patients on IgG therapy suffered fewer
infections per patient year (0.74) than adults (2.13). 6/14
patients showed deteriorating respiratory status despite adequate
therapy. Health questionnaires revealed a significant burden of
respiratory disease on a patient’s life.
Conclusion Clinical data showed patients with congenital
agammaglobulinemia receiving immunoglobulin therapy
retained a higher than average infection rate, most of which
affected mucosal barriers. Most patients self-reported worse
respiratory symptoms, a lower respiratory-related QoL and a
lower general health QoL relative to a healthy population.
Most participants had progressive structural lung damage
and decreased lung function. These results suggest that current
management is not entirely effective at preventing deteriora-
tion of respiratory health or restoring QoL.
Keywords XLA . agammaglobulinemia . immunoglobulin .
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Introduction
X-linked agammaglobulinemia (XLA) accounts for 85 % of
cases of primary agammaglobulinemia [1–3]. It is due to
mutations in Bruton’s tyrosine kinase (BTK) which en-
codes a hematopoietic-specific enzyme playing a critical
role in B lymphocyte development and receptor signaling
[1–3]. Other patients can suffer from recognized autosomal
recessive forms (e.g. μ chain) [4]. The resulting agamma-
globulinemia significantly contributes to the clinical char-
acteristics, as immunoglobulins are pivotal in the humoral
response, particularly in protecting against encapsulated
bacteria [5, 6]. Patients are adequately protected against
most non-bacterial pathogens, with the exception of en-
teroviruses, which can cause severe meningoencephalitis,
arthritis or enteritis, and Giardia lamblia, which causes
enteritis [7–9]. The mean age at diagnosis of XLA has
improved overtime to 3.5 years old, with a clear correlation
between prompt diagnosis and improved long-term patient
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outcome due to reduced baseline end-organ damage from ear-
ly infections [3, 7, 10].
Treatment involves life-long replacement of IgG, either
subcutaneously or intravenous, and judicious prophylactic an-
tibiotic use. Patients on immunoglobulin replacement therapy
have reduced episodes of systemic infection such as encepha-
litis, meningoencephalitis and sepsis [7]. However, the efficacy
in reducingmucosal infections, in particular those affecting the
sinopulmonary tract, is less clear. Some studies have suggested
that repeated low-grade infections of the sinopulmonary tract
can lead to significant, progressive chronic lung disease and
hearing difficulties [11, 12]. When first described, life expec-
tancy for patients with XLA was in the early 20s but now
patients survive into their fourth decade and beyond [13, 14].
However, there are few data on the long-term impact of this
condition and its management on patients’ outcomes, for ex-
ample, frequency of mucosal infections, progressive lung dam-
age and health-related quality of life (HRQoL).
This retrospective, cross-sectional study of patients with
XLA and autosomal recessive agammaglobulinemia in the
northern region of England documented the number and type
of infective episodes both pre- and post-instigation of immu-
noglobulin replacement therapy, and assessed respiratory sta-
tus and health, with lung function alongside radiological in-
vestigations, and determined evidence of progressive respira-
tory deterioration. The subsequent impact on quality of life of
patients and their careers was also assessed.
Methods
Patients in the northern region of England who had a defini-
tive or probable diagnosis of XLA as per the PAGID guide-
lines were included [15].
Definitive: less than 2 % CD19+ B lymphocytes and at
least one of the following:
& Mutation in Btk
& Absent or diminished Btk protein expression
& Maternal cousins, uncles or nephews with less than 2 %
CD19+ B lymphocytes
Probable: less than 2 % CD19+ B lymphocytes and at least
one of the following:
& Onset of recurrent bacterial infections in the first 5 years of
life
& Serum IgG, IgM and IgA more than 2 SD normal for age
& Absent isohemagglutinins and/or poor response to
vaccines
& Other causes of hypogammaglobulinemia have been
excluded
In addition, patients with proven autosomal recessive
agammaglobulinemias (e.g. μ heavy chain deficiency) and
less than 2 % CD19+ lymphocytes were included.
Assessment of current management of patients was con-
ducted using a standard proforma to collect information from
medical records. Presentation and age at diagnosis, infective
signs and symptoms pre- and post-diagnosis, and initiation of
Ig therapy, other treatment received, hospital admissions and
any surgical treatment were recorded. Where available, labo-
ratory analysis of current B lymphocyte count, IgG trough
levels and BTK protein expression were also recorded.
Age of diagnosis was recorded according to clinical judg-
ment and not molecular analysis, as clinical judgment coin-
cidedwith Ig therapy instigation, whereas molecular diagnosis
was often confirmed much later.
An infective episode was recorded if symptoms were sug-
gestive of an infection and antibiotics were prescribed. For
example, an episode with productive cough, colored sputum,
temperature and general malaise would be recorded as a re-
spiratory tract infection. If no symptomswere documented but
the diagnosis was recorded as an infection and treatment was
antibiotics, this was also recorded as an infection. When notes
recorded “recurrent” infections, an arbitrary frequency of
three infections per year was assigned. Due to the lack of
detail provided, this enabled a representation of the minimum
frequency of infections impliedwhilemaintaining consistency
throughout data collection.
Patients’ clinical information was gathered and compared
per individual pre- and post-Ig replacement therapy. Particular
attention was paid to any relevant investigations, inter alia,
high-resolution thoracic computerized tomography (HRCT),
chest radiographs and pulmonary function tests. Sequential
thoracic computerized tomography imaging reports were
compared from the initial scan to the most current, in order
to assess any level of change and any baseline damage. A
similar approach was taken when assessing pulmonary func-
tion results; FEV1 and FVC values were compared to the
predicted value, and this difference was then used to monitor
change over time. If the gap between the actual lung function
and the predicted value increased, this was used to indicate
deterioration. If the lung function was below the normal pre-
dicted value but no change occurred, this was recorded as
stable abnormal. If the difference between the achieved lung
function and the predicted value decreased, this was used to
show improved abnormal. If the lung function achieved rep-
resented the predicted value, this was reported as normal lung
function. Normal reference ranges, inter-test variability and
changes due to age were taken into account in this analysis
[16, 17].
The St George’s Respiratory Questionnaire (SGRQ) was
used to examine respiratory health. This is a well-recognized
tool, originally designed for patients with COPD and asthma,
but since used and validated in a number of studies for patients
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with bronchiectasis [18–20] and has been used in patients with
primary antibody deficiency [21]. The SGRQ assesses three
components of respiratory health: symptoms, activity and im-
pact. These scores were combined and the total compared to a
healthy person, equivalent to a score of 0. Therefore, the
higher the score that was achieved, the worse the health im-
pairment was. This data was compared against population
norms [22].
The Short-Form 36 version 2 (SF-36v2) [23] was used to
assess quality of life for patients aged 16 years and older. This
is a widely used tool to measure quality of life, is well vali-
dated and has been used in primary immunodeficiency [13,
24]. The SF-36v2 comprises of eight components, each scored
out of 100, with the best score being 100. These were com-
bined to give a physical health score and amental health score.
These data were compared against UK published norms [25].
Ethical approval was gained from the NRES committee
North East, Newcastle and North Tyneside 2, and written in-
formed consent was received from all participants prior to
enrolment.
Statistical Analysis
Data were analyzed in spss.v22 (www.spss.com). Non-
parametric data were displayed as median and range and
tested against population norms using the one-sample
Wilcoxon signed-rank test. Parametric data were displayed
as mean and standard deviation and differences were tested
against population groups using one-sample t test. Differences




Patients with congenital agammaglobulinemia were diag-
nosed and managed by the regional immunology center at
the Royal Victoria Infirmary (adults) or the Great North
Children’s Hospital, Newcastle upon Tyne. Fifteen patients
were identified from the local database, of which 14 had
XLA and 1 had mu chain-deficient autosomal recessive agam-
maglobulinemia. Available medical records of the 15 patients
were analyzed providing approximately 150 cumulative years
of past medical history.
The median age of study subjects was 26 years (range 5–
46); 9 were adults (range 22–46 years) and 6 children (range
5–16 years).
The median age at diagnosis in pediatric patients was
33 months (range 16–49 months). Age at diagnosis was avail-
able for 5 of the 9 adult patients with a median age at diagnosis
of 64 months (range 57–110 months). Therefore, the overall
median age at diagnosis was 49 months (range 16–
110 months). The median follow-up for pediatric patients
was 8 years 6 months, for adults (for whom data was avail-
able) 18 years 2 months with and an overall median follow-up
for the cohort of 10 years 6 months.
Three families had more than one affected child included in
the study, meaning that for 3 patients, there was a positive
family history (patients 10 and 12, 8 and 15, 11 and 13).
However, in none of the families was the second child
screened and all boys were subsequently symptomatic at time
of diagnosis. Therefore, all patients were diagnosed on clinical
history and symptoms.
Four patients had a mutation identified in BTK, a further 3
had absent BTK expression but no mutation was recorded.
Gene mutation data was unavailable for 6 patients. The one
female in our cohort had absent mu chain expression. There
were two patients with apparent normal BTK expression and
no mutation identified. However, these two patients were
brothers and diagnosed on this basis along with absent B lym-
phocytes. All except one (with very low B lymphocyte num-
bers—patient 9) had absent B lymphocytes and all those for
whom data at diagnosis was available (6 patients) had low or
absent immunoglobulins (Table 1).
Prophylactic Therapies
Seven (3 children, 4 adults) out of the 15 patients received
intravenous immunoglobulin therapy (IVIG) with the remain-
ing 8 (3 children, 5 adults) on subcutaneous immunoglobulin
(SCIG). Fourteen out of 15 patients had persistent IgG trough
levels >6 g/dl (5 of whom had trough levels of 6–7 g/dl, 9 of
whom had trough levels >8 g/dl). There was one adult patient
with recent persistent IgG trough levels of 4–5 g/dl; this pa-
tient showed slight progress of minor bronchiectasis onHRCT
scans. There was no significant difference in IgG trough levels
between those on SC and those on IV replacement therapy
(p=0.385).
Infections
All patients continued to experience infections after com-
mencing immunoglobulin therapy, the majority of which were
mucosal and affected the sinopulmonary tract. However, no
patient experienced invasive or systemic infections, while
there were seven such episodes prior to starting immuno-
globulin therapy (Table 2).
The pediatric infection rate on immunoglobulin therapy
dropped from 2.9 to 0.74 infections/patient/year. (The dataset
was incomplete to determine the number of infections/year
pre-immunoglobulin administration for the adult patients.)
The pediatric infection rate while receiving immunoglobulin
therapy was lower than that for adults receiving immuno-
globulin therapy (0.74 vs 2.12 infections/patient/year).
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The proportion of infections that were mucosal increased
following commencement of immunoglobulin replacement in
both pediatric (36 to 66 %) and adult (59 to 81 %) patients.
Specifically, the proportion of sinopulmonary infections as a
percentage of total infections increased post-immunoglobulin
therapy in pediatric (36 to 50 %) and adult (43 to 51 %)
patients.
Clinical Imaging and Lung Function
Successive computerized tomography thoracic images were
available for 14 participants. Eight patients had evidence of
bronchiectasis, 5 of whom showed progression of their lung
disease while on immunoglobulin replacement therapy. There
was pulmonary function data available for 12 patients, 2 of
whom had deteriorating pulmonary function tests while on
immunoglobulin therapy (Table 3). Of the 14 patients for
whom radiological and/or respiratory function information
was available, 8 had radiological evidence of bronchiectasis
of which 6 demonstrated either functional and/or structural
pulmonary deterioration after diagnosis and commencement
of immunoglobulin therapy. One patient in our cohort suffered
from severe bronchiectasis as result of his XLA and
underwent a lung transplantation. Out of the 6 patients who
showed a worsening of their bronchiectasis, 4 had IgG trough
levels consistently >10 g/dl (Table 4). IgG trough levels
tended to be higher in those patients with bronchiectasis but
this did not reach statistical difference (p=0.073).
St George’s Respiratory Questionnaire
Questionnaire data were collected from 12 patients; 1 was
unavailable to contact, 1 failed to return the questionnaires
and 1 patient was incapable due to significant learning diffi-
culties secondary to meningitis. SGRQ scores were compared
Table 1 Patient characteristics, Ig levels at diagnosis, B lymphocyte percentages, BTK expression and presence of mutation
Patient number Age Immunoglobulin levels at diagnosis (g/dl) CD19+ B lymphocytesa BTK expression Mutation
IgG IgA IgM Diagnosis Current
1 Pediatric 0.34 <0.05 0.084 <1 % <1 % Absent N/A
2 Pediatric <1.5 <0.02 <0.3 <1 % <1 % Diminished Unknown
3 Pediatric N/A N/A N/A N/A <1 % Absent Unknown
4 Pediatric <0.33 <0.07 <0.11 <1 % <1 % Absent Yes (c.877C>T)
5 Pediatric <0.33 <0.7 <0.08 <2 % <1 % Absent N/A
6 Pediatric 0.5 <0.07 0.33 <1 % <1 % Absent Yes (c.1911delA)
7 Adult N/A N/A N/A <1 % <1 % Absent Yes (R225X)
8 Adult N/A N/A N/A N/A <1 % Absent Unknown
9 Adult N/A N/A N/A N/A 6 % Absent No
10 Adult N/A N/A N/A N/A <1 % Normal N/A
11 Adult N/A N/A N/A N/A <1 % Absent Unknown
12 Adult N/A N/A N/A <1 % <1 % Normal N/A
13 Adult N/A N/A N/A 7 % <1 % Absent Unknown
14 Adult N/A N/A N/A N/A <1 % Absent Yes (c.863G>A)
15 Adult 2.9 <0.48 0.15 N/A <1 % N/A Unknown
N/A not available
a As percentage of total lymphocyte count
Table 2 Total number and type of infections pre- and post-instigation of
replacement immunoglobulin therapy (mean time to diagnosis = 49months,
mean follow-up time=14.7 years)
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against published normative data for Spanish males aged
40–49 (Table 5) [22].
The SGRQ showed a median score of 17.21 (1.05–64.65),
significantly higher than the published population normative
median of 2.72 (0–22.62, p=0.005). Each component of the
SGRQ was significantly higher than population norms
(Table 5), indicating a higher rate of respiratory disease and
burden than a healthy population. Patients with bronchiectasis
had significantly worse SGRQ scores in all domains com-
pared to a healthy population. Those without bronchiectasis
had significantly worse scores than a healthy population only
in symptom and impact domains. Compared to the patients
without bronchiectasis, those with bronchiectasis had signifi-
cantly worse scores for activity and tended to have to a worse
activity and overall total score (p=0.055 in both domains).
There was no significant difference in the symptom scores
between the two groups (p=0.522).
Short-Form 36 Version 2
SF-36v2 questionnaires were returned for all 9 adult partici-
pants; however, one form was incomplete and therefore ex-
cluded from further analyses. The results showed no signifi-
cant difference between the patients’ QoL compared to
healthy UK norms, except for the component ‘General
Health’ which was significantly worse in the congenital
agammaglobulinemia group (59.5 (SD 30.25) vs 78.3 (SD
15.61), p=0.012) [25] (Table 6).
Discussion
This is the first UK study examining a homogenous cohort of
congenital agammaglobulinemic patients in order to deter-
mine pulmonary health and health-related QoL. Since the first
description of congenital agammaglobulinemia by Bruton,
such patients have been treated with immunoglobulin replace-
ment and antibiotic prophylaxis [26, 27]. Immunoglobulin
replacement has been refined from intramuscular administra-
tion, intravenous replacement and now commonly subcutane-
ous administration [28]. Effective treatment helps prevent sig-
nificant life-threatening infections, but given the role of B
lymphocytes in antigen presentation, and the fact that only
IgG is replaced, significant sequelae may continue to develop
in these patients, even when receiving immunoglobulin sub-
stitution therapy.
This study clearly shows that, despite treatment, patients
with congenital agammaglobulinemia are not infection free
and retain a higher than average susceptibility to mucosal
infections. Although IgG is effective to some degree at
preventing mucosal infections, our data suggest that this alone
is not satisfactory at controlling mucosal and respiratory in-
fections. This would seem logical given the absence of IgA
Table 3 Patient’s lung function tests
Patient number Current lung functiona Previous lung functionb
FEV1 (% predicted) FVC (% predicted) FEV1/FVC ratio FEV1 (% predicted) FVC (% predicted) FEV1/FVC ratio
1 N/A N/A N/A N/A N/A N/A
2 N/A N/A N/A N/A N/A N/A
3 1.70 (72 %) 2.05 (78 %) 82 % 1.5 (69 %) 2.1 (86 %) 71 %
4 1.94 (72 %) 2.42 (79 %) 77 % 0.85 (59 %) 1.08 (70 %) 63 %
5 2.1 (50 %) 3.25 (66 %) 59 % 1.1 (51 %) 1.6 (64 %) 63 %
6 2.0 (90 %) 2.4 (92 %) 83 % 1.55 (83 %) 1.65 (76 %) 94 %
7 4.1 (85 %) 4.15 (73 %) 99 % 3.28 (79 %) 3.62 (75 %) 91 %
8 3.37 (84 %) N/A N/A 3.54 (88 %) 3.96 (85 %) 89 %
9 2.75 (88 %) 4.79 (95 %) 78 % 3.85 (90 %) 5.0 (100 %) 77 %
10 4.2 (98 %) 5.35 (105 %) 79 % 3.7 (86 %) 5.01 (98 %) 74 %
11 3.43 (93 %) 4.02 (113 %) 85 % 3.46 (93 %) 4.65 (106 %) 74 %
12 3.2 4.13 77 % N/A N/A N/A
13c 0.75 (21 %) 1.53 (37 %) 49 % 0.82 (23 %) 1.55 (37 %) 53 %
14 3.5 (90 %) 4.0 (93 %) 79 % 3.42 (83 %) 4.3 (85 %) 80 %
15 N/A N/A N/A N/A N/A N/A
N/A not available
a Latest lung function from 2010 to 2012
b Previous lung function from 2005 to 2007
c Patient 13’s lung function pre-transplant
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and IgM in immunoglobulin replacement therapy, which
plays the major role in protecting mucosal surfaces. It may
also be due to using IgG from a different population donor
pool (e.g. the USA) highlighting the different strains of bac-
teria to which they are exposed. It may also be possible that
donor immunoglobulin exhibits less affinity than immuno-
globulins produced in local pulmonary lymphoid tissue [29].
Other studies have suggested IgG trough levels should be
targeted to prevent breakthrough infections and complications
in individual patients rather than trying to achieve a particular
trough IgG level [30, 31]. However, in our cohort, of the 6
patients who had evidence of worsening lung disease, 4 had
IgG trough levels >10 g/dl, perhaps hinting at the limitations
of current treatment strategies even with optimized IgG ther-
apy. Our data suggests that once bronchiectasis has developed,
its progression is very difficult to control. It is possible the
major determining factor in reducing lung disease is early
diagnosis and the prevention of bronchiectasis developing at
all in these patients.
Nearly all patients with proven bronchiectasis (6/8) showed
progression of their disease despite IgG therapy, one of whom
proceeded to lung transplantation. The notes for these patients
record only recurrent low-grade infections. Previous reports
have shown repeated, albeit low-grade, infections in the
sinopulmonary tract of patients with agammaglobulinemia
can lead to significant and progressive lung disease, and our
results appear to substantiate this [32]. We believe that regular
HRCTscans play an important role in the routine follow-up of
these patients, not only in the detection of lung disease in
patients with apparent low-grade infections but also in the
monitoring of the progression of disease and further optimi-
zation of IgG therapy.
Table 4 Ig route, trough levels, lung disease and co-morbidities for each patient
Patient
number
Ig route IgG trough level
(g/dl)a
Lung diseaseb Prophylactic antibiotics Co-morbidities
CT Lung function
1 IV 7.4 Not done Not done None Gastro-esophageal reflux
2 SC 7.1 Normal Not done None Eczema
3 SC 8.7 Progression Stable—obstructive None
4 IV 11.7 Stable disease Stable—obstructive Azithromycin 3×/week
5 SC 7.6 Stable disease Stable—obstructive None
6 SC 7.9 Normal Stable—normal None
7 SC 5.8 Progression Stable—restrictive None
8 SC 1.6 Stable disease Deterioration—obstructive None
9 IV 6.9 Normal Stable—normal None Deafness
10 SC 9.0 Normal Stable—normal None
11 IV 7.6 Normal Stable—normal None
12 SC 9.5 Normal Stable—normal Azithromycin 3×/week
13 IV 11.5 Progression (pre-transplant) Deterioration—obstructive
(pre-transplant)
Co-trimoxazole daily Lung transplant
14 IV 10.0 Progression Stable—normal None
15 IV 15.3 Progression Not done None Autism, epilepsy
aMean over the last 5 years
b From the previous 5 years
Table 5 Breakdown of SGRQ compared against normative data (completed by 12 patients) and further broken down to compare those with and
without bronchiectasis. Scores are displayed as median (range)











Symptoms 33.8 (6.32–83.59) 4.24 (0.0–32.60) 0.020 43.98 (13.34–83.59) 0.028 25.08 (6.32–62.75) 0.028 0.522
Activity 20.83 (0.0–92.51) 0.0 (0.0–29.31) 0.012 36.43 (0.0–92.51) 0.043 5.61 (0.0–31.42) 0.109 0.042
Impact 8.83 (0.0–50.64) 0.0 (0–15.1) 0.003 15.63 (6.68–50.64) 0.028 4.74 (0.0–21.18) 0.043 0.055
Total 17.21 (1.05–64.65) 2.72 (0–22.62) 0.005 27.78 (10.64–64.65) 0.028 8.38 (1.05–31.18) 0.116 0.055
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The majority of patients experience respiratory symptoms
to varying degrees (irrespective of whether or not a formal
diagnosis of bronchiectasis was made), which has led to a
reduced activity level and negative impact on their lives.
There is scant previous literature on self-reported HRQoL in
patients with XLA and autosomal recessive agammaglobulin-
emia. Our study clearly shows the majority of patients have
significant respiratory symptoms, which negatively impact on
their HRQoL. This is supported by work from Hurst et al.,
who found in a small cohort of patients with primary antibody
deficiency the impact of respiratory health is a major contrib-
uting factor to the patient’s QoL [21]. The SF-36 data showed
a general quality of life comparable with a UK healthy popu-
lation except for the component ‘General Health’ which was
significantly worse in the agammaglobulinemia group.
Similar quality of life scores have been found in other studies
examining QoL in adults with XLA. This contrasts with QoL
in children with agammaglobulinemia which has been report-
ed as significantly worse than the healthy population and other
chronic conditions such as diabetes [13, 33].
Like other published datasets, our cohort is small and cared
for by a single center for excellence, making statistical analy-
sis difficult and potentially masking any differences in QoL or
clinical characteristics. On a larger national scale, other differ-
ences in QoL may be found. Ascertaining this understanding
is vital since children born today with congenital agamma-
globulinemia can be expected to live into adulthood, and
therefore, effective treatment should be provided. Other stud-
ies have shown that living with XLA directly impacts a pa-
tient’s future family planning decisions and potentially that of
carrier relatives [6, 13]. For patients to be able to make in-
formed decisions regarding family planning, they must have
up-to-date and accurate information about treatment and
prognosis. Our study is also limited by an incomplete nature
of historical adult records, so ascertainment of historical infec-
tion rates is not possible. However, notes and data pertaining
to modern management strategies were available, making
meaningful comparison possible. For the 2 patients with
‘stable’ bronchiectasis, it was not possible to ascertain
whether or not this developed pre- or post-diagnosis of
congenital agammaglobulinemia.
Our study shows that despite current treatment regimens,
patients who still suffer frequent and recurrent infections are
unable to maintain predicted normal lung function, and this
therefore means that patients with congenital agammaglobu-
linemia still have a lower than normal QoL. The aim of treat-
ment for patients with congenital agammaglobulinemias
should be to maintain a quality of life equal to that of a healthy
population [33]; our pilot study suggests we are some way
short of this target. We propose to extend this research to a
large, national cohort. These data are vital to help evaluate
future treatment strategies such as gene therapy and hemato-
poietic stem cell transplantation and help evaluate the implan-
tation of a newborn screening program [34–36]. Further work
is needed to evaluate and optimize other interventions, specif-
ically prophylactic antibiotics and physiotherapy. Future ther-
apeutic research should be targeted towards tackling the fre-
quent mucosal infections, by either looking at other immuno-
globulin isotypes or restoring B lymphocyte function.
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